MIRA
INFORM REPORT
|
Report Date : |
07.10.2008 |
IDENTIFICATION
DETAILS
|
Name : |
MARSING & CO LTD A/S |
|
|
|
|
Registered Office : |
Agenavej 16 2670 Greve |
|
|
|
|
Country : |
Demark |
|
|
|
|
Financials (as on) : |
31.03.2008 |
|
|
|
|
Date of Incorporation : |
1943 |
|
|
|
|
Com. Reg. No.: |
84320013 A/S |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Wholesale of Pharmaceutical Goods |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
DK 3.500.000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Company ID
Main name MARSING & CO LTD A/S
Main address AGENAVEJ 16
City 2670 GREVE
Country Denmark
Phone-no. +45-43-959697
Fax-no. +45-43-959600
Nat. partner ID-no. 202329
ID-/Reg.-no. 84320013 A/S
Legal form Limited company
Company Status Active
Activity
Activity 46.46
Wholesale of pharmaceutical goods
No of employees empl 25
Management Information
Management TAGE JOHANNES
BORVANG
EVA
BERIT KRISTENSEN
Board of directors JAYADEV V.
HIREMATH (Chairman of the board)
FINN
SØNDERGAARD (Member of the board)
BIMAL K. RAIZADA (Member of the board)
FARID RASHID
GULMOHAMED (Member of the board)
Historical Data
Established 1943
Registered 1978-08-22
Credit Facilities
Bankers NORDEA BANK DANMARK A/S ERHVERVSAFDELING KØBENHAVN
- VESTE
Financial data
Currency Danish Krone
Closing date
2008-03-31 2007-03-31 2006-03-31
Source Ann.
report Ann. report Ann.
report
Turnover
116.262.000
124.563.000 154.539.000
Costs
111.743.000
134.609.000 161.003.000
Ordinary result
-2.554.000 -20.668.000 -13.209.000
Tax
4.800.000 783.000 207.000
Annual result
-7.354.000 -21.451.000 -13.416.000
<* Assets *>
Fixed assets
28.372.000 42.824.000 47.514.000
Current assets
98.984.000 77.837.000 102.203.000
<* Liabilities *>
Equity capital
18.380.000 18.691.000 41.915.000
Share capital
18.800.000 8.800.000 8.800.000
Long-term debts
14.000.000 14.000.000
Short-term debts
94.976.000 87.970.000 107.802.000
<* Company Ratios *>
Gearing I
-1.090,63 -422,53 -1.925,38
Acid test ratio I 104,22 88,48 94,81
Acid test ratio II
82,96 63,28 62,88
Return on investment
3,55 -8,33 -4,32
Return on equity
-13,90 -110,58 -31,51
Solvency ratio
14,43 15,49 28,00
Property
Property No
Corporate Structure
Parent company HIKAL
INTERNATIONAL BV (76%)
Subsidiaries DANSK PULVER
& TABLETFABRIK LTD APS (ID:207120)
- (100%)
MEDIPHARMA LTD. A/S (ID:207122) (100%)
INTSEL CHIMOS SA (100%)
STERI-SUMA LTD APS (ID:207121) (100%)
MARSING & CO AFRICA (PROPRIETARY) LTD
(60%)
MARSING - MEDITALIA SRL (100%)
BREMER PHARMA GMBH (100%)
MORRIS COMPANY LIMITED (100%)
Associated business JSL HOLDING
NETHERLANDS BV (24%)
Secondary names(s) MARSING A/S
MARSING GENERICS A/S
Payment profile
Payment profile Payment
regular
Credit Summary
Credit limit Estimated
3.500.000
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs. |
|
UK Pound |
1 |
Rs. |
|
Euro |
1 |
Rs. |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)